A clinical trial that investigated erlotinib combined with onartuzumab, an antibody against MET, has shown promising results in preclinical and phase II clinical studies but failed to demonstrate significant results in the phase III trials that compared erlotinib with or without onartuzumab in previously treated patients with EGFR-positive MET-overexpressed NSCLC.28 Here, MET is linked to non-small cell lung carcinoma.